Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24587311 | 0.82 | PPARG (0.40) | MTNR1BPTGER4CHRM2CHRM1CHRM3 | |
| SCHEMBL18213808 | 0.82 | RORC (0.43) | RORCMTNR1BPTGER4MRGPRX4PPARG | |
| SCHEMBL12093575 | 0.82 | CHRM2 (0.50) | MTNR1BCHRM2CHRM1CHRM3FFAR4 | |
| SCHEMBL24587369 | 0.79 | PPARG (0.40) | MTNR1BCHRM2CHRM1CHRM3PPARG | |
| SCHEMBL20256607 | 0.79 | SLC6A4 (0.38) | RORCMTNR1BMRGPRX4PPARGPPARA | |
| SCHEMBL4680033 | 0.79 | MRGPRX4 (0.40) | MTNR1BPTGER4MRGPRX4PPARGPPARA | |
| SCHEMBL12474356 | 0.79 | PPARG (0.37) | RORCMTNR1BPTGER4MRGPRX4PPARG | |
| SCHEMBL18585144 | 0.79 | MTNR1B (0.40) | RORCMTNR1BPTGER4MRGPRX4PPARG | |
| SCHEMBL12474349 | 0.78 | CHRM2 (0.35) | RORCMTNR1BPTGER4CHRM2CHRM1 | |
| SCHEMBL12016019 | 0.74 | IDO1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771320-B2 | Carbocyclic sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160326103-A1 | CARBOCYCLIC SULFONE ROR GAMMA MODULATORS | BRISTROL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326103-A1 | CARBOCYCLIC SULFONE ROR GAMMA MODULATORS | RORC, RORB, RORA | P2RX7 1064/4885RORC 1/4885MTNR1B 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.